Asaf Danziger
CIK: 0001654435
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)5 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NVCR
NovoCure Ltd
Director
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 30, 2026NVCR
NovoCure Ltd
Award(A)Direct268 shares at avg. $11.15$3K - Dec 31, 2025NVCR
NovoCure Ltd
Award(A)Direct1 shares at avg. $10.99$10.99 - Jun 30, 2025NVCR
NovoCure Ltd
Award(A)Direct833 shares at avg. $15.13$13K - Jan 1, 2025NVCR
NovoCure Ltd
Award(A)Direct400K shares- - Dec 31, 2024NVCR
NovoCure Ltd
Award(A)Direct412 shares at avg. $14.75$6K
1-5 of 5 transactions
About Danziger Asaf
Danziger Asaf (SEC CIK 0001654435) files insider reports with the SEC as Director of NovoCure Ltd (NVCR).
Signal8 holds 4 ownership filings by Danziger Asaf (3 Form 4, 1 Form 5), filed between Jan 3, 2025 and Jul 1, 2026. Those filings report 5 transactions, from Dec 31, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Danziger Asaf's filings is in WAYNE, PA.
Recent filings by Danziger Asaf
- Jun 30, 2026: Grant or award of NVCR shares (Form 4, code A).
- Dec 31, 2025: Grant or award of NVCR shares (Form 5, code A).
- Jun 30, 2025: Grant or award of NVCR shares (Form 4, code A).
- Jan 1, 2025: Grant or award of NVCR shares (Form 4, code A).
- Dec 31, 2024: Grant or award of NVCR shares (Form 4, code A).
Other insiders filing for NovoCure Ltd (NVCR)
- Puri Michal Nath, Chief Human Resources Officer
- Leonard Frank X, Chief Executive Officer
- Ben Arye Barak, General Counsel
- LEUNG GABRIEL, Director
- Stafford Kristin, Director
- Ocean Allyson J, Director